Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - Gastroenterology, 2006 - Elsevier
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …
被引用次数：152 相关文章

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - …, 2006 - gastrojournal.org
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.

E Gallmeier, ES Calhoun, C Rago, JR Brody… - …, 2006 - europepmc.org
Methods We endogenously disrupted FANCC and FANCG in a human adenocarcinoma cell
line and determined the impact of these genes on drug sensitivity, irradiation sensitivity, and …
[PDF] academia.edu

[PDF][PDF] Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E GALLMEIER, ES CALHOUN, C RAGO… - …, 2006 - academia.edu
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …

[引用][C] Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - Gastroenterology, 2006 - cir.nii.ac.jp
Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model
for Specific Therapeutic Options | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - …, 2006 - ohsu.elsevierpure.com
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - …, 2006 - pure.johnshopkins.edu
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …
[PDF] psu.edu

[PDF][PDF] Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, SC Cunningham… - …, 2006 - Citeseer
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …

Targeted Disruption of FANCC and FANCG in Human Cancer Provides a Preclinical Model for Specific Therapeutic Options

E Gallmeier, ES Calhoun, C Rago, JR Brody… - Gastroenterology, 2006 - infona.pl
Background & Aims: How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options

E Gallmeier, ES Calhoun, C Rago… - …, 2006 - pubmed.ncbi.nlm.nih.gov
Background & aims How specifically to treat pancreatic and other cancers harboring
Fanconi anemia gene mutations has raised great interest recently, yet preclinical studies …